Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical and biotechnology industry [2]. Core Insights - The upcoming ADA conference is highlighted as a significant event for the GLP-1 industry chain, with expectations of increased market activity and visibility for Chinese innovative drug companies [4][11]. - Recent strategic collaborations in the industry, such as between Hansoh Pharmaceutical and Regeneron, and BMS with BioNTech, indicate a robust investment environment and potential for growth in innovative drug development [11]. - The report emphasizes the importance of the GLP-1 sector, suggesting specific companies to watch, including Zai Lab, Boryung Pharmaceutical, and others involved in GLP-1 innovation and supply chain [11]. Summary by Sections 1. Industry Overview - The pharmaceutical and biotechnology sector reported a weekly return of 1.13%, ranking 17th among 31 primary sub-indices [9]. - Over the past month, the sector achieved a return of 6.48%, ranking 2nd among the same indices [9]. 2. Market Performance and Valuation - The current PE (TTM) for the pharmaceutical and biotechnology industry is 28.18 times, which is below the historical average of 31.15 times [17][20]. - The industry has shown a relative performance of 4.76% against the CSI 300 index over the past month, indicating strong market positioning [23]. 3. Market Tracking - The chemical pharmaceutical sub-sector has shown the highest weekly return of 1.67% and a monthly return of 10.92% [33]. - Notable individual stock performances include Yiming Pharmaceutical and Wanbangde, with significant weekly increases of 33.09% and 32.59%, respectively [35]. 4. Industry and Company Dynamics - Recent policy updates from the Guangdong Provincial Medical Insurance Bureau aim to enhance drug procurement processes, indicating a move towards a more standardized and competitive market [44]. - Key industry news includes the approval of a nine-valent HPV vaccine by Wantai Biological Pharmacy and ongoing clinical trials for chronic hepatitis B treatments [45].

Core Insights - The total trading volume of non-monetary ETFs reached 207.207 billion yuan on June 6, 2025, with 47 ETFs exceeding a trading volume of 1 billion yuan [1] - The Short-term Bond ETF, Credit Bond ETF, and Shanghai Company Bond ETF led the market in trading volume, with respective volumes of 9.861 billion, 9.829 billion, and 9.501 billion yuan [1] - The Benchmark National Debt ETF, S&P 500 ETF, and National Debt Policy Financial Bond ETF had the highest turnover rates, at 518.01%, 173.17%, and 153.90% respectively [1] Trading Volume Summary - The Short-term Bond ETF (511360.SH) had a trading volume of 9.861 billion yuan, with a 49.58% increase from the previous trading day and a turnover rate increase of 49.31% [1] - The Shanghai Company Bond ETF (511070.SH) recorded a trading volume of 9.501 billion yuan, with a 15.68% increase from the previous trading day and a turnover rate increase of 11.65% [2] - The S&P 500 ETF (159612.SZ) saw a trading volume increase of 214.66% from the previous trading day, reaching a volume of 3.47 billion yuan [2] Turnover Rate Summary - The Benchmark National Debt ETF (511100.SH) had the highest turnover rate at 518.01% [6] - The S&P 500 ETF (159612.SZ) had a turnover rate of 173.17%, indicating significant trading activity [6] - The National Debt Policy Financial Bond ETF (511580.SH) had a turnover rate of 153.90% [6] ETF Performance Summary - The Short-term Bond ETF increased by 0.01% on the day, with a 0.04% increase over the past 5 days and a 0.14% increase over the past 20 days [1] - The Shanghai Company Bond ETF rose by 0.08% on the day, with a 0.03% increase over the past 5 days and a 0.45% increase over the past 20 days [2] - The S&P 500 ETF increased by 0.81% on the day, with a 2.69% decrease over the past 5 days but an 8.98% increase over the past 20 days [2] Industry and Thematic ETFs - The industry-themed ETFs included the Hong Kong Innovative Drug ETF, which had a trading volume of 4.956 billion yuan [1] - The Hong Kong Innovative Drug ETF (159316.SZ) had a recent trading volume of 1.8 billion yuan and increased by 2.56% on the day [8] - The National Life 500 ETF (510560.SH) had a trading volume of 1.26 billion yuan and experienced a significant amplitude increase of 1133.56% [7]

Group 1 - The Hong Kong stock market saw a high opening but closed lower, with the innovative drug sector initially weakening before rebounding. Notable stocks included Green Leaf Pharmaceutical rising over 5%, and others like Kangnuo Pharmaceutical-B, United Pharmaceutical, and CSPC Pharmaceutical rising over 2% [1] - The Hong Kong innovative drug ETF (159567) experienced a net inflow of over 80 million yuan in the past 20 trading days, indicating high market interest [1] - Leading domestic innovative pharmaceutical companies showcased their achievements at the ASCO annual meeting, with Heng Rui Pharmaceutical presenting four studies as oral reports and five as rapid oral reports, highlighting their academic and clinical significance [1] Group 2 - The innovative drug ETF (159567) tracks the Guozheng Hong Kong Stock Connect Innovative Drug Index, with 90% of its weight in innovative drug companies, making it the highest among all medical theme indices, poised to benefit from trends like AI-enabled drug development and the international expansion of domestic innovative drugs [2] - The innovative drug ETF (159992) tracks the innovative drug index, which includes leading companies in the innovative drug industry chain, benefiting from AI advancements and the introduction of a new insurance category for high-priced innovative drugs [2] - East Wu Securities noted that China's innovative drug licensing transactions are entering a booming phase, driven by improved internal R&D capabilities and increased international trust in Chinese drug pipelines [2]

Group 1 - The pharmaceutical sector has recently experienced a significant pullback, with the innovative drug concept seeing a net outflow of nearly 2.5 billion yuan in A-shares [1] - The Tianhong Innovative Drug ETF (517380) reached a new high for the year before experiencing a substantial decline, dropping 2.75% with a trading volume of 22 million yuan, and most constituent stocks fell nearly 5% [1] - The Tianhong Innovative Drug ETF is the only product tracking the Hang Seng-Hu-Shen-Hong Kong Innovative Drug Selected 50 Index, which includes leading innovative drug companies from the three markets [1] Group 2 - Dongwu Securities predicts that 2025 will mark the explosive growth of China's innovative drug industry, driven by three core factors: significant BD transactions, profitability turning points for leading companies, and an improving policy environment [2] - Guosheng Securities acknowledges short-term trading pullback risks but emphasizes the solid underlying logic and clear trends in the innovative drug sector, maintaining a positive outlook for the innovative drug bull market [2] - The market size of China's innovative drugs is expected to exceed 2 trillion yuan by 2030, with a compound annual growth rate of 24.1% [2]

Market Performance - As of June 4, 2025, the Shanghai Composite Index rose by 0.42% to 3376.20 points, while the Shenzhen Component Index increased by 0.87% to 10144.58 points, and the ChiNext Index climbed by 1.11% to 2024.93 points [1] - The total trading volume of both markets reached 1.15 trillion yuan, marking the fifth consecutive day of exceeding one trillion yuan [1] - The jewelry sector showed strong performance with a daily increase of 5.95%, followed by leisure food and personal care products, which rose by 4.45% and 3.37% respectively [1] ETF Performance - A total of 1049 non-currency ETFs in the market increased, with an increase ratio of 91% [1] - The Hang Seng Innovative Drug Index rose by 3.83%, with related ETFs also showing significant gains of 3.61% and 3.55% [1] - The latest share size of the Hang Seng Innovative Drug ETF (520500.SH) reached 366 million shares, closely tracking the performance of the Hang Seng Innovative Drug Index [3] Valuation Metrics - The latest P/E ratio (PE-TTM) for the Hang Seng Innovative Drug Index is 26.92, which is lower than the average of over 11.03% in the past three years [4] - The P/E ratio for the Hang Seng Hong Kong Stock Connect Innovative Drug Index stands at 26.64, also below the average of over 12.16% in the last three years [5] - The National Certificate Hong Kong Stock Connect Innovative Drug Index has a P/E ratio of 29.36, lower than the average of over 10.84% in the past three years [5] Declining ETFs - A total of 71 non-currency ETFs declined, with a decrease ratio of 6% [5] - The top declining ETFs included the Greater Bay Area ETF, which fell by 1.41%, and the Transportation ETF, which decreased by 0.82% [7] Premium Rates - The S&P 500 Consumer Select Index showed a premium of 24.67%, while the S&P 500 Index had a premium of 17.11% [8] - The top ETFs by premium rate included the S&P Consumer ETF (24.67%) and the S&P 500 ETF (17.11%) [10]

Quantitative Models and Construction Methods 1. Model Name: Hong Kong Stock Multi-Factor Model - **Model Construction Idea**: The model integrates four categories of factors: technical, capital flow, fundamental, and analyst expectations, to evaluate Hong Kong Stock Connect constituent stocks[38][39] - **Model Construction Process**: 1. Select Hong Kong Stock Connect constituent stocks as the sample universe 2. Construct four categories of factors: - **Technical factors**: Indicators derived from price and volume data - **Capital flow factors**: Metrics based on fund flow data, such as net inflow - **Fundamental factors**: Metrics like valuation ratios (e.g., PE, PB) and profitability indicators (e.g., ROE) - **Analyst expectation factors**: Metrics based on analyst ratings and earnings forecasts 3. Combine these factors into a composite score for each stock 4. Rank stocks based on their composite scores and select the top 20 stocks to form the portfolio[38][39][40] - **Model Evaluation**: The model demonstrates strong performance in historical backtesting, with significant excess returns over the benchmark[38][40] 2. Model Name: Hong Kong Stock Preferred 20 Portfolio - **Model Construction Idea**: This portfolio is constructed monthly by selecting the top 20 stocks with the highest composite scores from the multi-factor model, using equal weighting[40] - **Model Construction Process**: 1. At the end of each month, rank stocks based on their composite scores from the multi-factor model 2. Select the top 20 stocks 3. Allocate equal weights to each stock in the portfolio 4. Use the Hong Kong Composite Index (HKD, 930930.CSI) as the benchmark for performance comparison[40] - **Model Evaluation**: The portfolio has shown robust performance over the long term, with a high excess annualized return and a stable risk-return profile[40][44] --- Model Backtesting Results 1. Hong Kong Stock Multi-Factor Model - **Excess Annualized Return**: 13.3% (2015.1–2025.5)[40][44] - **Excess Annualized Volatility**: 13.4%[44] - **Excess Sharpe Ratio**: 1.0[44] - **Maximum Drawdown**: 18.2%[44] 2. Hong Kong Stock Preferred 20 Portfolio - **May 2025 Monthly Return**: 2.44%[40] - **May 2025 Excess Return**: -2.36% (Benchmark return: 4.80%)[40] - **Excess Annualized Return**: 13.3% (2015.1–2025.5)[40][44] - **Excess Annualized Volatility**: 13.4%[44] - **Excess Sharpe Ratio**: 1.0[44] - **Maximum Drawdown**: 18.2%[44] --- Quantitative Factors and Construction Methods 1. Factor Name: Technical Factors - **Factor Construction Idea**: Derived from price and volume data to capture market trends and momentum[38][39] - **Factor Construction Process**: 1. Calculate indicators such as moving averages, RSI, and MACD 2. Normalize and rank the indicators across the stock universe 3. Combine the normalized scores into a composite technical factor score[38][39] 2. Factor Name: Capital Flow Factors - **Factor Construction Idea**: Based on fund flow data to identify stocks with strong capital inflows[38][39] - **Factor Construction Process**: 1. Measure net fund inflows for each stock 2. Normalize and rank the net inflow data 3. Combine the normalized scores into a composite capital flow factor score[38][39] 3. Factor Name: Fundamental Factors - **Factor Construction Idea**: Focused on valuation and profitability metrics to identify undervalued stocks with strong fundamentals[38][39] - **Factor Construction Process**: 1. Calculate valuation ratios (e.g., PE, PB) and profitability indicators (e.g., ROE) 2. Normalize and rank these metrics across the stock universe 3. Combine the normalized scores into a composite fundamental factor score[38][39] 4. Factor Name: Analyst Expectation Factors - **Factor Construction Idea**: Based on analyst ratings and earnings forecasts to capture market sentiment and expectations[38][39] - **Factor Construction Process**: 1. Collect analyst ratings and earnings forecast data 2. Normalize and rank the data 3. Combine the normalized scores into a composite analyst expectation factor score[38][39] --- Factor Backtesting Results 1. Technical Factors - **Performance**: Demonstrated strong predictive power in identifying stocks with upward momentum[38][39] 2. Capital Flow Factors - **Performance**: Effective in capturing stocks with significant fund inflows, indicating strong market interest[38][39] 3. Fundamental Factors - **Performance**: Successfully identified undervalued stocks with robust financial performance[38][39] 4. Analyst Expectation Factors - **Performance**: Provided valuable insights into market sentiment and future earnings potential[38][39]

Group 1 - The US government is pressuring countries to submit their best trade negotiation proposals by June 4, including tariffs and quotas for purchasing US agricultural products, or face punitive measures [1] - The Chinese government is tightening controls to prevent illegal outflow of strategic minerals, with various provinces enhancing regulatory measures [2] - The weakening of the US dollar is becoming a consensus among Wall Street banks, with the ICE dollar index down 8.9% year-to-date, leading to a rise in gold prices [3] Group 2 - Circle, a major stablecoin company, is set to go public on June 5, marking the first IPO in the stablecoin sector, which has positively impacted related stocks [4] - The Chinese government has issued new policies to improve the electricity service environment, which is expected to lower costs for small private enterprises and benefit power equipment companies [7] - Pharmaron, a leading CRO, is expanding its reach into overseas markets by investing in a healthcare fund, with a significant increase in revenue and new orders reported [8][10]

Market Overview - The Hong Kong stock market showed a collective rebound with the Hang Seng Index rising by 1.53% to close at 23,512.49 points, the Tech Index up by 1.08% to 5,189.49 points, and the National Enterprises Index increasing by 1.92% to 8,519.86 points [2] - The financial sector exhibited strong performance, with notable gains in major banks and securities firms [3][4] Financial Sector Performance - Major banks such as Industrial and Commercial Bank of China rose by 3.02%, China Construction Bank by 3.47%, Agricultural Bank of China by 3.41%, and Bank of China by 2.67% [3][4] - Securities firms also performed well, with Huatai Securities increasing by 3.70% and Guotai Junan by 2.94% [3][4] - Insurance stocks saw positive movement, with Ping An Insurance up by 1.86% and China Life Insurance by 1.39% [3][4] IPO Market Dynamics - According to CICC, nearly 50 A-share companies are planning to list in Hong Kong, with 23 having submitted materials or received approval [7] - Three main drivers for the IPO surge include comprehensive policy support, improved market attractiveness, and companies' internationalization strategies [7] - CICC estimates that the liquidity demand for these upcoming listings will be approximately HKD 150 billion to HKD 180 billion, equivalent to about 0.7 days of the average daily trading volume on the Hong Kong main board since the beginning of the year [7] Sector Highlights - The automotive sector led the market gains, with companies like Li Auto and BYD seeing increases of 5.82% and 3.94%, respectively, driven by positive sales data [6] - The pharmaceutical sector also performed well, with companies such as Green Leaf Pharmaceutical and Four Rings Pharmaceutical rising by 8.98% and 8.51%, respectively, due to recent approvals for innovative drugs [6][7] Investment Trends - There is a notable increase in institutional investment in bank stocks, driven by their stable asset quality and high dividend returns [5] - The expansion of passive funds and the high weighting of banks in major indices have contributed to the positive sentiment in the financial sector [5]

6月3日，A股、港股市场集体上涨，创新药板块概念股持续走强。 相关ETF方面，截至收盘，创新药ETF天弘（517380）涨2.24%，年内累计涨幅达23.08%，位居全市场 行业类ETF涨幅第一，涨幅领先第二名超9%。成分股中，睿智医药涨超13%，亚盛医药-B涨超8%，华 海药业、联邦制药、和黄医药、贝达药业等股涨超7%。 创新药ETF天弘(517380)及联接基金(A类014564，C类014565)是全市场唯一一只跟踪恒生沪深港创新药 精选50指数的产品，该指数覆盖了沪、深、港三地创新药龙头，十大权重股包括百济神州、药明康德、 恒瑞医药、泰格医药等细分领域龙头，可谓是创新药"浓度"极高。同时，该ETF及联接基金（A类： 014564，C类：014565）采用量化指标优化，截至6月3日收盘，年内累计涨幅位居全市场行业类ETF涨 幅第一。 招银国际表示，我们认为，受益于创新药出海交易、国内集采政策优化、创新药丙类医保目录落地、医 疗设备招标复苏、内需复苏等积极因素推动，医药行业有望在 2025 年继续迎来估值修复。 消息面上，据第一财经，5月30日，在陆家嘴金融沙龙上，中国科学院院士马大为表示，我们有越来越 ...

Group 1 - The A-share and Hong Kong stock markets saw a strong performance in the innovative drug sector, with the Tianhong Innovative Drug ETF (517380) closing up 2.24%, ranking first among innovative drug ETFs and twelfth in the overall ETF market, with a trading volume exceeding 11 million yuan [1] - The Tianhong Innovative Drug ETF was launched in 2021 and tracks the "Hang Seng Shanghai-Shenzhen Hong Kong Innovative Drug Selected 50" index, providing comprehensive coverage of the innovative drug industry across A-shares and Hong Kong stocks [1] - Key stocks in the ETF included Ruizhi Pharmaceutical, which rose over 13%, along with other notable gainers such as Tigermed, Hutchison China MediTech, Federal Pharmaceutical, and Huahai Pharmaceutical [1] Group 2 - Hansoh Pharmaceutical announced a licensing agreement with Regeneron Pharmaceuticals for the global exclusive rights to develop, produce, and commercialize HS-20094, excluding mainland China, Hong Kong, and Macau, with an upfront payment of $80 million and potential milestone payments of up to $1.93 billion [2] - The innovative drug sector is expected to continue being a primary focus for pharmaceutical investments, driven by increasing policy support and a shift from quantity and speed to quality and innovation in Chinese innovative drugs [4] - The number of original research drugs entering clinical stages in China has reached 704, surpassing the United States and positioning China as the global leader in this area [3]